Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

BETHESDA, Md., March 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2007. As a result of the reverse merger between Micromet AG and CancerVax Corporation that was completed on May 5, 2006, the financial information included below for the fiscal year 2006 consists of Micromet AG's historical financial results for the period of January 1, 2006 to May 5, 2006 without the inclusion of the financial results of CancerVax, and the combined results of the two companies thereafter.

Summary of Recent Events:

-- Micromet published data on its BiTE(R) antibody MT103 at the annual

meeting of the American Society of Hematology in December, showing that

MT103 induces dose-dependent objective complete and partial responses

in late stage lymphoma patients. The BiTE antibody could also clear the

bone marrow and other infiltrated organs from tumor cells. Particularly

encouraging was the observation of complete responses in patients with

mantle cell lymphoma (MCL) -- a disease that is difficult to treat. In

Europe, Micromet has initiated a phase 2 study in acute lymphoblastic

leukemia, one of the most aggressive blood cancers.

-- Micromet has completed preclinical development for its second BiTE

antibody MT110. MT110 binds to EpCAM, a cell surface molecule that is

highly expressed on many solid tumors and on cancer stem cells -- those

cancer cells responsible for metasta
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... 5, 2015 The Biosimilars Forum ... members Reps. Joe Barton (R-TX) and ... of 33 House members, for their leadership in sending ... for the Centers for Medicare & Medicaid Services (CMS), ... CMS,s 2016 Medicare Physician Fee Schedule proposed rule. As ...
(Date:8/5/2015)... 2015  MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" ... company, announces the posting of the following Letter to ... Hansen to the Company,s website at www.mabvax.com ... have invested in MabVax Therapeutics because you share our ... difficult cancers.  You also share our excitement about our ...
(Date:8/5/2015)... , Aug. 5, 2015 GenomeDx Biosciences announced ... at 9:45 a.m. ET on Wednesday, August 12, in ... GenomeDx, will provide an update about the company,s Decipher ® ... About Decipher ® The Decipher ®  Prostate ... test for men with intermediate and high risk prostate cancer. ...
(Date:8/5/2015)... Switzerland (PRWEB) , ... August 05, 2015 , ... ... solutions for production, culture, and assessment of more organotypic 3D cell culture models, ... GravityTRAP™ Ultra-Low Attachment (ULA) Plates are now available for purchase exclusively ...
Breaking Biology Technology:Biosimilars Forum Applauds Reps. Barton, Eshoo for Leadership on Proposed Medicare Rule on Biosimilar Coding 2Biosimilars Forum Applauds Reps. Barton, Eshoo for Leadership on Proposed Medicare Rule on Biosimilar Coding 3MabVax Therapeutics Issues Letter to Stockholders 2MabVax Therapeutics Issues Letter to Stockholders 3MabVax Therapeutics Issues Letter to Stockholders 4MabVax Therapeutics Issues Letter to Stockholders 5MabVax Therapeutics Issues Letter to Stockholders 6MabVax Therapeutics Issues Letter to Stockholders 7MabVax Therapeutics Issues Letter to Stockholders 8MabVax Therapeutics Issues Letter to Stockholders 9MabVax Therapeutics Issues Letter to Stockholders 10MabVax Therapeutics Issues Letter to Stockholders 11MabVax Therapeutics Issues Letter to Stockholders 12MabVax Therapeutics Issues Letter to Stockholders 13GenomeDx Biosciences to Present at 2015 Wedbush PacGrow Healthcare Conference 2GenomeDx Biosciences to Present at 2015 Wedbush PacGrow Healthcare Conference 3InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms 2InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms 3
... ARBOR, Mich.---A delicate balance of atomic forces can be ... size---an attribute that,s important for many nanotech applications but ... The same type of forces are at work ... inorganic supercluster structures in this research are in many ...
... announced today they have been named to the prestigious 30th ... entrepreneurial and fastest growing companies in America. The 2011 Inc. ... past three years.  HumanTouch is ranked 203 on this list. ... representatives of the Inc. 500 such as Zappos, Patagonia, Intuit ...
... 2011 Biotechnology leader Divine Skin Inc. (DSKX) posted ... quarter. The expanding innovator of personal care solutions credits ... sales, which are 79 percent ahead of the same ... has been keeping up with demand," said Divine Skin ...
Cached Biology Technology:Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 3
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... particularly carbon dioxide (CO2), have been associated with ... grasslands, drainage of the land, and land use ... have led scientists to measure soil organic carbon ... to evaluate how changes in tillage practices affect ...
... major challenges facing the international community in the coming century. ... the distribution of the sea ice, and has led to ... close connection between the Arctic climate and our own. The ... to the polar front extending south, for example. Researchers ...
... tympanoplasty can be performed successfully in 95 percent of ... study in the February 2013 issue of OtolaryngologyHead ... frequently performed procedure with varying reported success rates ranging ... membrane repair success in children is often perceived as ...
Cached Biology News:New protocol recommendations for measuring soil organic carbon sequestration 2New protocol recommendations for measuring soil organic carbon sequestration 3New protocol recommendations for measuring soil organic carbon sequestration 4Aarhus University builds research station in North Greenland 2Aarhus University builds research station in North Greenland 3
... a clone of the human Topoisomerase II gene. ... the topological state of nucleic acids by passing ... which generates a separate DNA helix (1,2) . ... mechanism, the enzyme can relax negatively or positively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: